Aldeyra Therapeutics, Inc.

ALDX

$192M

Micro Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaLEXINGTON8 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 17, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 0 past

🎯PDUFANext

FDA PDUFA Date reproxalap (standard)

2/17/2026

For dry eye disease. NDA filing. Extracted from SEC filing: 8-K

Source

🎯PDUFA

FDA PDUFA Date reproxalap (standard)

3/17/2026

For dry eye disease. NDA filing. Extracted from SEC filing: 8-K

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Reproxalap Ophthalmic Solution (0.25%)

Phase 3

Dry Eye Syndromes

Vehicle Ophthalmic Solution

Phase 3

Dry Eye

Vehicle Opthalmic Solution

Phase 3

Dry Eye

ADX-102 1% Topical Dermal Cream (reproxalap)

Phase 3

Sjogren-Larsson Syndrome

ADX-2191 (intravitreal methotrexate 0.8%)

Phase 3

Proliferative Vitreoretinopathy

Vehicle of ADX-102 Ophthalmic Solution

Phase 3

Non-infectious Anterior Uveitis

Reproxalap Ophthalmic Solution (0.25%) QID

Phase 3

Dry Eye

Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID

Phase 3

Dry Eye

ADX-102 Ophthalmic Solution (0.5%)

Phase 3

Dry Eye Syndromes

Reproxalap Ophthalmic Solution (0.5%)

Phase 3

Allergic Conjunctivitis

ADX-102 Ophthalmic Drops (0.5%)

Phase 2

Conjunctivitis, Allergic

ADX-2191

Phase 2

Retinitis Pigmentosa

ADX-629

Phase 2

Ethanol Intoxication

Active topical NS2 1% dermatologic cream

Phase 2

Sjögren-Larsson Syndrome

ADX-629 (Open-label)

Phase 2

Atopic Dermatitis

Xiidra® (5% lifitegrast ophthalmic solution)

Phase 2

Dry Eye

NS2 Ophthalmic Drops (0.5%)

Phase 2

Allergic Conjunctivitis

NS2

Phase 2

Non-infectious Anterior Uveitis

Reproxalap Ophthalmic Solution (0.1%)

Phase 2

Dry Eye Syndrome

Drug Name	Phase	Indication	Designations
Reproxalap Ophthalmic Solution (0.25%)	Phase 3	Dry Eye Syndromes	-
Vehicle Ophthalmic Solution	Phase 3	Dry Eye	-
Vehicle Opthalmic Solution	Phase 3	Dry Eye	-
ADX-102 1% Topical Dermal Cream (reproxalap)	Phase 3	Sjogren-Larsson Syndrome	-
ADX-2191 (intravitreal methotrexate 0.8%)	Phase 3	Proliferative Vitreoretinopathy	-
Vehicle of ADX-102 Ophthalmic Solution	Phase 3	Non-infectious Anterior Uveitis	-
Reproxalap Ophthalmic Solution (0.25%) QID	Phase 3	Dry Eye	-
Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID	Phase 3	Dry Eye	-
ADX-102 Ophthalmic Solution (0.5%)	Phase 3	Dry Eye Syndromes	-
Reproxalap Ophthalmic Solution (0.5%)	Phase 3	Allergic Conjunctivitis	-
ADX-102 Ophthalmic Drops (0.5%)	Phase 2	Conjunctivitis, Allergic	-
ADX-2191	Phase 2	Retinitis Pigmentosa	-
ADX-629	Phase 2	Ethanol Intoxication	-
Active topical NS2 1% dermatologic cream	Phase 2	Sjögren-Larsson Syndrome	-
ADX-629 (Open-label)	Phase 2	Atopic Dermatitis	-
Xiidra® (5% lifitegrast ophthalmic solution)	Phase 2	Dry Eye	-
NS2 Ophthalmic Drops (0.5%)	Phase 2	Allergic Conjunctivitis	-
NS2	Phase 2	Non-infectious Anterior Uveitis	-
Reproxalap Ophthalmic Solution (0.1%)	Phase 2	Dry Eye Syndrome	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

ALDX News